Startseite Kongressberichte & Archiv 15th International Conference on Malignant Lymphoma (ICML) NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS

NON-CLINICAL AND EARLY CLINICAL DATA WITH NEW COMBINATIONS

A.R. Mato, New York, NY (USA), et al.

PHASE I/II STUDY OF UMBRALISIB (TGR-1202) IN COMBINATION WITH UBLITUXIMAB (TG-1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER’S TRANSFORMATION

Authors Conclusion from the abstractThe triple combination of umbralisib + ublituximab + pembrolizumab was well‐tolerated. Responses were durable in BTK refractory, high risk pts, including two CRs in RT pts. Data suggests that time‐limited therapy could be possible. Enrollment is ongoing in both the CLL and RT cohorts and an amendment is planned to evaluate the triplet combination of U2 + TG‐1501 (PD‐L1 mAb).

 

S.D. Smith, Seattle, WA (USA), et al.

PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL

Authors Conclusion from the abstractP + RCHOP did not show toxicity beyond what is expected with RCHOP, and was associated with a high CR rate in this trial. FDG avid lesions in pts with PR were commonly false positives. Significant PDL‐1 tumor staining was seen in most pts tested, and appears to predict PFS; final PDL‐1 results will be presented. Our data supports further comparative study of P+RCHOP in DLBCL.

 

C.S. Tam, Melbourne (Australia), et al.

ZANUBRUTINIB PLUS OBINUTUZUMAB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR RELAPSED/ REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) 

Authors Conclusion from the abstractThe combination of zanubrutinib plus obinutuzumab was generally well tolerated and active in patients with CLL/SLL and R/R FL. Few patients discontinued due to AEs. A Phase 2 trial comparing zanubrutinib plus obinutuzumab against obinutuzumab alone in R/R FL is ongoing.

 

T. Shree, Stanford, CA (USA), et al.

A PHASE I/II TRIAL OF IBRUTINIB, INTRATUMORAL CPG AND LOCAL RADIATION IN PATIENTS WITH LOW- GRADE B-CELL LYMPHOMA: INTERIM CLINICAL AND CORRELATIVE RESULTS

Authors Conclusion from the abstractEarly data suggest that the combination of oral ibrutinib, intratumoral CpG, and local low‐dose radiation is safe and can generate systemic antitumor immune responses and systemic tumor shrinkage in low‐grade lymphoma.

 

C. Diefenbach, New York, NY (USA), et al. 

EXTENDED FOLLOW-UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN RESEARCH GROUP (E4412)

Authors Conclusion from the abstractAll combinations were well tolerated, with mainly grade 1‐2 immune toxicities, however deaths secondary to pneumonitis were noted in N containing cohorts. The ORR and CR rate in the N containing cohorts is superior to that of B‐I doublet; the CR of B‐N‐I is higher than both doublet combinations and some patients have durable responses. It remains to be seen if a higher CR rate will eventually translate into more durable response rates. The ongoing randomized phase 2 study (E4412) is comparing the B‐N doublet to the B‐N‐I triplet (NCT01896999).

 

T.E. Cummin, Southampton (UK), et al.

HIGH EXPRESSION OF BCL-2 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA CONFER POOR PROGNOSIS BUT MAY BE REVERSIBLE BY COMBINED INHIBITION WITH BET INHIBITORS AND BH3 MIMETICS.

Authors Conclusion from the abstractWe identified a varied landscape of expression of anti‐apoptotic BCL‐2 proteins in DLBCL and highlighted the contribution of high BCL‐xL expression to treatment resistance in DLBCL. High expression of anti‐apoptotic BCL‐2 family members also provides resistance to BETi. However, this could be overcome by use of specific BH3‐mimetics targeting the relevant pro‐survival BCL‐2 member, involving mitochondrial priming.